GlassScriptPhysician profile
Anjuli Michele Eagleston
NPI 1134785876
$5,796.84
in general payments reported to CMS, 2019-2025
35 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $62.21 · 2021: $20.00 · 2022: $15.46 · 2023: $538 · 2024: $2,787 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,581.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.60 | 2023-2025 | Qulipta, Linzess, Viberzi |
| Lundbeck LLC | $649.38 | 2023-2025 | Rexulti, Vyepti |
| Novo Nordisk INC | $563.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $401.93 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $377.64 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $283.18 | 2023-2024 | Spravato |
| Pfizer INC. | $260.71 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.30 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $148.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $138.72 | 2023-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $133.12 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $131.51 | 2024-2025 | Fanapt |
| Teleflex LLC | $109.22 | 2024 | Urolift |
| Novartis Pharmaceuticals Corporation | $106.28 | 2024-2025 | |
| Astellas Pharma US INC | $100.41 | 2024-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $99.79 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.84 | 2019-2025 | Jardiance |
| Corium, LLC | $72.48 | 2024-2025 | Azstarys |
| Exact Sciences Corporation | $59.54 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $57.45 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $56.76 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $51.32 | 2024-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $45.33 | 2023-2024 | Auvelity |
| Inspire Medical Systems, INC. | $44.58 | 2024-2025 | Inspire |
| Amgen INC. | $38.46 | 2023-2025 | Prolia, Evenity, Repatha |
| Esperion Therapeutics, INC. | $38.00 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2023-2024 | Trintellix |
| Aimmune Therapeutics, INC. | $35.32 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.92 | 2022-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $23.50 | 2023 | Belsomra |
| Mylan Specialty L.P. | $22.19 | 2024 | Yupelri |
| Optinose US, INC. | $21.61 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.11 | 2024 | Opsumit, Uptravi |
| Halozyme INC | $17.29 | 2023 | |
| Avanos Medical | $16.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Eagleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.